A Yale-led randomized placebo-controlled trial in 2009 tested it specifically for fibromyalgia: both the treatment group and the placebo group improved, which suggests a strong placebo or volume-expansion effect on top of any direct nutrient benefit
If your doctor is on our side (I know that some are) please ask them to support this petition and share it with their colleagues
It also states plainly that compounded medications are not FDA-approved as branded products, so they do not carry the approval or the clinical trial evidence branded versions hold
Test characteristics Species Human Sample types Serum and EDTA plasma Sample volume 25 L Assay range 0.9 - 940 pmol/L (2.8 - 2940 pg/mL) Detection limit 0.65 pmol/L Incubation 2h + 15 min Detection method Chemiluminescence specificity The following cross-reactions have been tested: GLP-1 (1-36) amide 88% GLP-1 (7-36) amide 93% GLP-1 (9-36) amide 100% GLP-1 (1-37) Not detected GLP-1 (7-37) Not detected Glucagon Not detected GIP Not detected GLP-2 Not detected Oxyntomodulin Not detected Glicentin Not detected Miniglucagon Not detected MPGF Not detected Liraglutide Not detected Exenatide Not detected Lixisenatide Not detected Dulaglutide 0.07% directions for use Certificate of Analysis directions for use Certificate of Analysis SAFETY DATA SHEET technical notes For technical notes specific to Mercodia Total GLP-1 ELISA see: TN34-0154 Sample collection and handling for Mercodia Total GLP-1 ELISA (10-1278-01) references Stinson, S
Therapeutic advances in rheumatoid arthritis
Novo Nordisk continues to face legal and financial repercussions as concerns grow over whether the drug causes serious, life-changing side effects
